Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR1080)
Drug Name
Mianserin
Synonyms
Mianserin [INN:BAN]; Mianserina; Mianserina [INN-Spanish]; Mianserine; Mianserine [INN-French]; Mianserinum; Mianserinum [INN-Latin]; Mianseryna; Mianseryna [Polish]; Lerivon; Norval; UEQUQVLFIPOEMF-UHFFFAOYSA-N; mianserin; 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine; 2-Methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine; 24219-97-4; BRN 0755346; C18H20N2; CHEBI:51137; CHEMBL6437; DSSTox_CID_3317; EINECS 246-088-6; HSDB 7182; NCGC00015656-06
Indication Depression [ICD11: 6A71] Phase 4 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 264.4 Topological Polar Surface Area 6.5
Heavy Atom Count 20 Rotatable Bond Count 0
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 2
Cross-matching ID
PubChem CID
4184
PubChem SID
5025442 ; 7979983 ; 8152618 ; 11336019 ; 11361258 ; 11364714 ; 11367276 ; 11369838 ; 11373110 ; 11374958 ; 11378002 ; 11462230 ; 11466127 ; 11467247 ; 11484722 ; 11485733 ; 11489019 ; 11491651 ; 11493074 ; 11495624 ; 14848151 ; 26752015 ; 29223290 ; 46508096 ; 47291183 ; 47365243 ; 47440310 ; 47515362 ; 47515363 ; 47589044 ; 47736534 ; 47810801 ; 47885463 ; 48035179 ; 48110499 ; 48110500 ; 48334548 ; 48416276 ; 49698341 ; 49962249 ; 50104682 ; 56464297 ; 57322182 ; 74414799 ; 85209455 ; 85787314 ; 85787904 ; 90341017 ; 92308680 ; 92719300
ChEBI ID
ChEBI:51137
CAS Number
24219-97-4
TTD Drug ID
D0R6RO
Formula
C18H20N2
Canonical SMILES
CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42
InChI
1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3
InChIKey
UEQUQVLFIPOEMF-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
(R)-mianserin,8-hydroxy DM002665
154699696
Oxidation - Hydroxylation 1 [6]
(R)-mianserin,N-Desmethyl DM002666
153935
Oxidation - N-Dealkylation 1 [6]
(R)-mianserin,N-oxide DM002664
29984837
Oxidation - N-Oxidation 1 [6]
8-hydroxyminaserin DM002661
162817
Oxidation - Hydroxylation 1 [6]
N-desmethylmianserin DM002663
115194
Oxidation - N-Oxidation 1 [6]
8-hydroxy-N-desmethylmianserin DM002662
195998
Oxidation - 8-Hydroxylation 2 [6]
8-hydroxy-N-desmethylmianserin DM002662
195998
Oxidation - N-Dealkylation 2 [6]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR001669 Mianserin 8-hydroxyminaserin Oxidation - Hydroxylation CYP2D6 ... [6]
MR001670 Mianserin N-desmethylmianserin Oxidation - N-Oxidation CYP1A2 ... [6]
MR001671 Mianserin (R)-mianserin,N-oxide Oxidation - N-Oxidation CYP3A4 [6]
MR001672 Mianserin (R)-mianserin,8-hydroxy Oxidation - Hydroxylation CYP3A4 ... [6]
MR001673 Mianserin (R)-mianserin,N-Desmethyl Oxidation - N-Dealkylation CYP2D6 ... [6]
MR001667 8-hydroxyminaserin 8-hydroxy-N-desmethylmianserin Oxidation - N-Dealkylation CYP2C19 ... [6]
MR001668 N-desmethylmianserin 8-hydroxy-N-desmethylmianserin Oxidation - 8-Hydroxylation CYP1A2 ... [6]
⏷ Show the Full List of 7 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 1A2 (CYP1A2) DME0003 Homo sapiens
CP1A2_HUMAN
1.14.14.1
[2]
Cytochrome P450 2B6 (CYP2B6) DME0020 Homo sapiens
CP2B6_HUMAN
1.14.14.1
[3]
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[4]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[5]
Mephenytoin 4-hydroxylase (CYP2C19) DME0021 Homo sapiens
CP2CJ_HUMAN
1.14.14.1
[2]
References
1 Seizures following the withdrawal of long-term treatment with mianserin. Ital J Neurol Sci. 1988 Apr;9(2):167-9.
2 Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther. 1996 Jul;278(1):21-30.
3 Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003 Oct;13(10):619-26.
4 Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy. Psychiatr Pol. 2004 Nov-Dec;38(6):1093-104.
5 [Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6.
6 Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.